Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-19 |
ADCOCK INGRAM Jun-14 |
AUROBINDO PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 830 | 383 | - | |
Low | Rs | 527 | 276 | - | |
Sales per share (Unadj.) | Rs | 333.9 | 113.9 | - | |
Earnings per share (Unadj.) | Rs | 40.4 | -28.7 | - | |
Cash flow per share (Unadj.) | Rs | 51.8 | -23.8 | - | |
Dividends per share (Unadj.) | Rs | 2.50 | 0 | - | |
Dividend yield (eoy) | % | 0.4 | 0 | - | |
Book value per share (Unadj.) | Rs | 237.1 | 89.4 | - | |
Shares outstanding (eoy) | m | 585.91 | 168.78 | - | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 2.0 | 2.9 | 70.2% | |
Avg P/E ratio | x | 16.8 | -11.5 | -146.4% | |
P/CF ratio (eoy) | x | 13.1 | -13.9 | -94.6% | |
Price / Book Value ratio | x | 2.9 | 3.7 | 77.6% | |
Dividend payout | % | 6.2 | 0 | - | |
Avg Mkt Cap | Rs m | 397,569 | 55,608 | 714.9% | |
No. of employees | `000 | 17.9 | 4.3 | 415.9% | |
Total wages/salary | Rs m | 25,849 | 3,490 | 740.6% | |
Avg. sales/employee | Rs Th | 10,956.9 | 4,476.9 | 244.7% | |
Avg. wages/employee | Rs Th | 1,447.7 | 813.0 | 178.1% | |
Avg. net profit/employee | Rs Th | 1,324.3 | -1,128.1 | -117.4% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 195,636 | 19,219 | 1,017.9% | |
Other income | Rs m | 1,553 | 135 | 1,154.0% | |
Total revenues | Rs m | 197,189 | 19,354 | 1,018.9% | |
Gross profit | Rs m | 39,519 | -3,331 | -1,186.6% | |
Depreciation | Rs m | 6,680 | 829 | 805.3% | |
Interest | Rs m | 2,626 | 521 | 504.4% | |
Profit before tax | Rs m | 31,767 | -4,546 | -698.8% | |
Minority Interest | Rs m | 27 | -13 | -213.1% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -881 | 0 | - | |
Tax | Rs m | 7,269 | 284 | 2,558.8% | |
Profit after tax | Rs m | 23,645 | -4,843 | -488.2% | |
Gross profit margin | % | 20.2 | -17.3 | -116.6% | |
Effective tax rate | % | 22.9 | -6.2 | -366.2% | |
Net profit margin | % | 12.1 | -25.2 | -48.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 153,645 | 14,076 | 1,091.5% | |
Current liabilities | Rs m | 120,429 | 7,920 | 1,520.6% | |
Net working cap to sales | % | 17.0 | 32.0 | 53.0% | |
Current ratio | x | 1.3 | 1.8 | 71.8% | |
Inventory Days | Days | 135 | 111 | 121.9% | |
Debtors Days | Days | 64 | 124 | 51.4% | |
Net fixed assets | Rs m | 103,909 | 8,205 | 1,266.4% | |
Share capital | Rs m | 586 | 89 | 656.6% | |
Net worth | Rs m | 138,908 | 15,085 | 920.8% | |
Long term debt | Rs m | 1,800 | 5,301 | 33.9% | |
Total assets | Rs m | 264,544 | 28,497 | 928.3% | |
Interest coverage | x | 13.1 | -7.7 | -169.4% | |
Debt to equity ratio | x | 0 | 0.4 | 3.7% | |
Sales to assets ratio | x | 0.7 | 0.7 | 109.7% | |
Return on assets | % | 9.9 | -15.2 | -65.5% | |
Return on equity | % | 17.0 | -32.1 | -53.0% | |
Return on capital | % | 23.8 | -19.8 | -120.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,220 | 1,640 | 988.7% | |
From Investments | Rs m | -28,768 | -504 | 5,711.3% | |
From Financial Activity | Rs m | 19,191 | 4,811 | 398.9% | |
Net Cashflow | Rs m | 6,656 | 5,948 | 111.9% |
Compare AUROBINDO PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare AUROBINDO PHARMA With: JUBILANT PHARMOVA ELDER PHARMA ALEMBIC PHARMA GSK PHARMA NOVARTIS
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.
More